Pfizer COVID Pill Showed No Benefit Among Younger Adults
Research from Israel is raising doubts regarding the use of Paxlovid as a go-to treatment for COVID-19. The report on this was written by Matthew Perrone and was published by the Associate Press last August 25, 2022.
Perrone reports on the results of a study involving 109,000 patients which found that Paxlovid had no measurable benefit among people aged 40 to 65 years.
Paxlovid was authorized by the US Food and Drug Administration for use among people aged 12 years and older.
The report adds that an earlier study conducted by Pfizer showed that Paxlovid offered no benefit to healthy adults, regardless of vaccination status.
Editor’s Note: It is surprising to see an article like this in mainstream media because we all know that they are a tool for COVID propaganda.
This then makes us wonder: why are they suddenly telling the truth? Could it be that Big Pharma money is not flowing freely when it comes to Covid pills? [See Will Pfizer’s COVID pill end the pandemic?].
Read Original Article
Read Online
Click the button below if you wish to read the article on the website where it was originally published.
Read Offline
Click the button below if you wish to read the article offline.
